Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M S Tallman

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995
Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemiaM S Tallman, D Hakimian, C Zanzig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemiaD Hakimian, M S Tallman, D K Hogan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical OncologyC L Bennett, M R Bishop, M S Tallman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive diseaseC Nabhan, L Rundhaugen, M Jatoi, et al.
Blood|September 15, 1996
Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experienceM S Tallman, D Hakimian, A W Rademaker, et al.
Leukemia & Lymphoma|January 24, 2003
Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphomaC Nabhan, L A Peterson, S A Kent, et al.
Bone Marrow Transplantation|June 15, 2007
Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports projectC C Tigue, J M McKoy, A M Evens, et al.
Leukemia & Lymphoma|October 8, 1999
Technetium-99m sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosineR S Siegel, D Hakimian, W Spies, et al.
Leukemia & Lymphoma|March 18, 2000
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision makingC L Bennett, T J Stinson, J H Laver, et al.
Bone Marrow Transplantation|August 3, 2005
Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSFM Tomblyn, L I Gordon, S Singhal, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1995
Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemiaM S Tallman, D Hakimian, C Zanzig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemiaD Hakimian, M S Tallman, D K Hogan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical OncologyC L Bennett, M R Bishop, M S Tallman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive diseaseC Nabhan, L Rundhaugen, M Jatoi, et al.
Blood|September 15, 1996
Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experienceM S Tallman, D Hakimian, A W Rademaker, et al.
Leukemia & Lymphoma|January 24, 2003
Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphomaC Nabhan, L A Peterson, S A Kent, et al.
Bone Marrow Transplantation|June 15, 2007
Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports projectC C Tigue, J M McKoy, A M Evens, et al.
Leukemia & Lymphoma|October 8, 1999
Technetium-99m sulfur colloid scanning and correlative magnetic resonance imaging in patients with hairy cell leukemia and hypocellular bone marrow biopsies after 2-chlorodeoxyadenosineR S Siegel, D Hakimian, W Spies, et al.
Leukemia & Lymphoma|March 18, 2000
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision makingC L Bennett, T J Stinson, J H Laver, et al.
Bone Marrow Transplantation|August 3, 2005
Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSFM Tomblyn, L I Gordon, S Singhal, et al.
Pageof 10